GlassScriptPhysician profile
Jacob A Ninan
NPI 1427009083
$830.84
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.03 · 2021: $20.82 · 2022: $34.73 · 2023: $166 · 2024: $321 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $341.84 | 2024-2025 | Bioprotect Balloon Implant System |
| Janssen Biotech, INC. | $78.78 | 2020-2023 | Darzalex |
| Merck Sharp & Dohme LLC | $75.48 | 2020-2025 | Keytruda, Lynparza |
| Pfizer INC. | $67.54 | 2024-2025 | |
| Beigene USA, INC. | $41.28 | 2022-2023 | Brukinsa |
| Astellas Pharma US INC | $34.15 | 2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $33.78 | 2023 | Imbruvica |
| Novartis Pharmaceuticals Corporation | $31.78 | 2025 | |
| Pharmacosmos Therapeutics INC. | $27.80 | 2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $21.51 | 2023 | Ultomiris |
| Puma Biotechnology, INC. | $20.95 | 2024 | |
| Amgen INC. | $20.82 | 2021 | |
| Abbvie INC. | $18.35 | 2025 | |
| Celgene Corporation | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Ninan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.